Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.
Copyright 2026 NPR
Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C.
